Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Varicella-Zoster Virus Infections in Patients Treated with Fingolimod
JAMA Neurol 72:31-39,10, Arvin, A.M.,et al, 2015
Viral Infections of the Nervous System, Chronic Meningitis, and Prior Diseases, Progressive Multifocal Leukoencephalopathy
Adams & Victors Principles of Neurology, Chp 33, pg 767, Ropper, A.H.,et al, 2014
Varicella-Zoster Virus Acute Myelitis in a Patient with MS Treated with Natalizumab
Neurol 80:1812-1813, Yeung, J.,et al, 2013
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
Progressive Multifocal Leukoencephalopathy: Prognosis and treatment
UpToDate, June, Koralnik, I.J.,et al, 2011
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
NEJM 361:1067-1074, Chen,Y.,et al, 2009
An Approach to the Diagnosis of Acute Transverse Myelitis
Semin Neurol 28:105-120, Jacob, A.,et al, 2008
Multiple Sclerosis After Infectious Mononucleosis
Arch Neurol 64:72-75, Nielsen,T.R.,et al, 2007
Reactivation of JC Virus and Development of PML in Patients With Multiple Sclerosis
Neurol 68:985-990, Khalili,K.,et al, 2007
Inflammatory Progressive Multifocal Leukoencephalopathy in Human Immunodeficiency Virus-Negative Patients
Ann Neurol 62:34-39, Huang,D.R.,et al, 2007
Characteristics and Antecedents of Progressive Multifocal Leukoencephalopathy in an Insured Population
Neurol 67:884-886, Eng,P.M.,et al, 2006
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Temporal Relationship Between Elevation of Epstein-Barr Virus Antibody Titers and Initial Onset of Neurological Symptoms in Multiple Sclerosis
JAMA 293:2496-2500, Levin,L.I.,et al, 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Epstein-Barr Virus in Pediatric Multiple Sclerosis
JAMA 291:1875-1879, Alotaibi,S.,et al, 2004
Relapsing-Remitting Multiple Sclerosis and Human Herpesvirus 6 Active Infection
Arch Neurol 61:1523-1527, Alvarez-Lafuente,R.,et al, 2004
Multiple Sclerosis and Epstein-Barr Virus
JAMA 289:1533-1536, Levin,L.I.,et al, 2003
Bacterial Infection as a Cause of Multiple Sclerosis
Lancet 360:352-353, Wolfson,C. &Talbot,P., 2002
Clinical and Neuroradiologic Features of Acute Disseminated Encephalomyelitis in Children
Neurol 56:1308-1312,1257, Hynson,J.L.,et al, 2001
Epstein-Barr Virus Antibodies and Risk of Multiple Sclerosis
JAMA 286:3083-3088,3127, Ascherio,A.,et al, 2001
Multiple Sclerosis and Antecedent Infections
Neurol 54:2307-2310, Marrie,R.A.,et al, 2000
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Herpes Simplex Virus in Postmortem Multiple Sclerosis Brain Tissue
Arch Neurol 53:125-133, 1231996., Sanders,V.J.,et al, 1996
Twelfth-Nerve Palsy:Analysis of 100 Cases
Arch Neurol 53:561-566, Keane,J.R., 1996
Acute Transverse Myelopathy:Spinal and Cranial MR Study with Clinical Follow-up
AJNR 16:115-123, Campi,A.,et al, 1995
Transverse Myelitis, Retrosp Analy of 33 Cases, with Diff Cases Assoc with MS & Parinfectious Events
Arch Neurol 50:532-535, Jeffery,D.R.,et al, 1993
Lack of JC Viral Sequences in Multiple Sclerosis Brain Tissue by Polymerase Chain Reaction
Ann Neurol 32:829-831, Buckle,G.J.,et al, 1992
Is JC Virus Latent in Brain?
Ann Neurol 29:433-434, Lipton,H.L., 1991
Implications of Progressive Multifocal Leukoencephalopathy and JC Virus for the Etiology of MS
Acta Neurol Scand 83:20-23, Stoner,G.L., 1991
Retroviruses and Multiple Sclerosis. I. Analysis of Seroreactivity by Western Blot and Radioimmune Assay
Neurol 40:1251-1253, Weinshenker,B.G.,et al, 1990
Retroviruses & Multiple Sclerosis. II. Failure of Gene Amplification Techniques to Detect Viral Sequences
Neurol 40:1254-1258, Dekaban,G.A.&Rice,G.P.A., 1990
Isolation of Herpes Simplex Virus Type 1 During First Attack of Multiple Sclerosis
Ann Neurol 26:283-285, Bergstrom,T.,et al, 1989
Neurologic Manifestations of AIDS
Medicine 66:407-437, McArthur,J.C., 1987
Recovery of Paramyxovirus from the Jejunum of Patients with Multiple Sclerosis
Lancet p. 117, May 28977., Prasad,I.,et al, 1977
Multiple Sclerosis:Diagnostic Usefulness of Cerebrospinal Fluid
Ann Neurol 2:425, Johnson,K.,et al, 1977
Isolated Facial Numbness
Ann Int Med 80:49, Horowitz,S., 1974
Fusion of Cultured Multiple-Sclerosis Brain Cells with Indicator Cells:Isolate of Parainfluenza-Type Virus
Lancet 7766, 1972, July., Meulen,V.,et al, 1972
Neurologic Manifestations of Long COVID Differ Based on Acute COVID-19 Severity
Ann Neurol 94:146-159, Giraldo,G.S.P.,et al, 2023
Acute Flaccid Myelitis: Cause, Diagnosis, and Management
Lancet 394:334-397, Murphy, O.C.,et al, 2021
Neurologic Features in Severe SARS-CoV-2 Infection
NEJM 382:2268-2270, e110, , 2020
Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young
NEJM 382:e61-e63, Oxley, T.J., et al, 2020
Preparing a Neurology Department for SARS-CoV-2 (COVID-19)
Neurol 94:886-891, Waldman, G.,et al, 2020
Fat Embolism Syndrome in Sickle Cell Disease
J Clin Med 9:1-12, Tsitsikas, D.A.,et al, 2020
Enterovirus Vaccines for an Emerging Cause of Brain-Stem Encephalitis
NEJM 370:792-794, McMinn, P.C., 2014